Elizabeth C. Neil

Dr. Elizabeth C. Neil

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2025 in Journal of Clinical Oncology
Verified
Journal Article
Open access
ALAndrew B. Lassman
Andrew B. Lassman
MPMei-Yin C. Polley
Mei-Yin C. Polley
FIFabio M. Iwamoto
Fabio M. Iwamoto
ASAndrew Sloan
Andrew Sloan
TWTony Wang
Tony Wang
MMMinesh p Mehta
Minesh p Mehta
PURPOSE: New therapies for glioblastoma are needed, especially MGMT -unmethylated (u MGMT ) disease. NRG Oncology BN002 (phase I) demonstrated safety and suggested efficacy of ipilimumab (ipi) with nivolumab (nivo) in newly diagnosed glioblastoma, leading to this phase II/III trial. METHODS: Adults with newly diagnosed u MGMT glioblastoma and Karnofsky performance status (KPS) ≥70 were randomly assigned to radiotherapy with either immunotherapy (ipi and nivo) or temozolomide (TMZ), stratified by recursive partitioning analysis (RPA) class and intention to use tumor treating fields. With 95% power to detect a hazard ratio (HR) ≤0.58 for progression-free survival (PFS) at a one-sided significance level ( P ) of .15, superior PFS with immunotherapy in phase II would lead to phase III overall survival (OS) testing. Corticosteroids were disallowed when starting immunotherapy. Diagnosis, biomarkers, and PFS were centrally assessed. RESULTS: One hundred fifty-nine participants were randomly assigned (79 immunotherapy and 80 TMZ). Arms were well balanced for age (median 60 years, range, 28-79), sex (male n = 105, 66%), KPS (90-100 n = 97, 61%), resection extent (gross total, n = 103, 65%), and RPA class (III, n = 16, 10%; IV, n = 116, 73%; V, n = 27, 17%). A preplanned analysis of phase II data conducted after 100 centrally determined PFS events showed no significant PFS improvement for ipi and nivo versus TMZ (median 7.7 months v 8.5 months, HR, 1.47 [70% CI, 1.19 to 1.83]; one-sided P = .96 [95% CI, 0.98 to 2.2]). OS is immature (>50% alive) but with no observed difference between arms (median approximately 13 months each, HR, 0.95 [95% CI, 0.61 to 1.49]; P = .36). CONCLUSION: Ipi and nivo did not improve PFS among patients with newly diagnosed u MGMT glioblastoma versus TMZ. Accrual closed permanently; the trial will not proceed to phase III. No new safety signals were identified. Molecular correlative analyses and survival follow-up are ongoing.

6 March 2020 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
BPBindi B. Parikh
Bindi B. Parikh
ENElizabeth C. Neil
Elizabeth C. Neil

12 November 2021 in Cureus
Verified
Journal Article
Open access
TETeresa P. Easwaran
Teresa P. Easwaran
DSDavid Sterling
David Sterling
CFClara Ferreira
Clara Ferreira
LSLindsey Sloan
Lindsey Sloan
CWChristopher T. Wilke
Christopher T. Wilke
KDKathryn E Dusenbery
Kathryn E Dusenbery
Glioblastoma recurrence between initial resection and standard-of-care adjuvant chemoradiotherapy (CRT) is a negative prognostic factor in an already highly aggressive disease. Re-resection with GammaTileⓇ (GT Medical Technologies Inc., Tempe, AZ) placement affords expedited adjuvant radiation to mitigate the likelihood of such growth. Here, we report a glioblastoma patient who underwent re-resection and GammaTileⓇ (GT) placement within two months of the initial gross total resection due to regrowth that reached the size of the original presenting tumor. The patient subsequently received concurrent temozolomide and 60 Gy external beam to regions outside of the brachytherapy range, fulfilling the generally accepted Stupp regimen. The patient tolerated the treatment without complication. The dosimetrics and implications of the case presentation are reviewed.

17 December 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
MMMarcus Milani
Marcus Milani
CCConstance Peace Chen
Constance Peace Chen
LSLindsey Sloan
Lindsey Sloan
ENElizabeth C. Neil
Elizabeth C. Neil
AYAnudeep Yekula
Anudeep Yekula
Liam ChenLiam Chen
Liam Chen
Background and Clinical Significance: DNA methylation profiling has revolutionized the classification of central nervous system (CNS) tumors, providing insights into tumor prognosis, recurrence, and personalized treatments. However, a significant challenge remains in classifying rare or molecularly undefined high-grade gliomas (HGGs) that fail to match existing methylation reference classes. This study evaluates the clinical, histopathological, and molecular characteristics of three unclassifiable cases through a retrospective analysis. Methylation profiling was performed by the National Institute of Health based on the 11b6 and 12b6 of the Heidelberg classifier, as well as the National Cancer Institute/Bethesda classifier. The cases were evaluated for histopathological features, molecular markers, and clinical outcomes. Case Presentation: We present three adult patients with histologically confirmed HGGs that were unclassifiable by standard DNA methylation profiling. All patients presented with diverse clinical and radiographic findings. Histopathological examination confirmed high-grade glial neoplasms in each case. However, methylation profiling failed to yield clear matches for any known class. Instead, profiling suggested indeterminate IDH-wildtype neoplasms with aggressive clinical courses. Following treatment, one patient experienced disease progression and died, while the other two remained without evidence of recurrence at follow-up. Conclusions: These cases underscore the persistent diagnostic challenges posed by CNS tumors that are unclassifiable by current DNA methylation, highlighting the urgent need for expanded reference datasets. While methylation profiling has transformed the field of tumor diagnostics, its limitations still exist. Enhanced collaboration to broaden diagnostic categories is essential to broaden diagnostic classifiers. Until these tools are refined, integration of clinical, histological, and molecular findings is imperative to optimize patient management, improve classification accuracy, and optimize therapeutic outcomes. Unclassifiable HGGs represent a critical gap in CNS tumor diagnostics. Addressing this requires global collaboration to enrich methylation databases. In the interim, a multimodal diagnostic strategy remains essential for the management of these challenging tumors.

14 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
MSMeghna Saxena
Meghna Saxena
EMElisabet Ampudia Mesias
Elisabet Ampudia Mesias
SDSumant Dhawan
Sumant Dhawan
SFStephen C Frederico
Stephen C Frederico
XCXiaoqing Cheng
Xiaoqing Cheng
MOMichael Olin
Michael Olin
Background: Immune checkpoint inhibition has transformed cancer therapy; however, many patients fail to respond to single-agent blockade, and combination strategies are often limited by toxicity. Central nervous system tumors exploit multiple immunosuppressive pathways, including the CD200 and PD1/PDL1 axis to evade anti-tumor immunity and support tumor aggressiveness. Methods: We investigated ARL200, a peptide ligand targeting the CD200 activation receptor (CD200AR) using in vitro immune assays, murine syngeneic tumor models, phosphoproteomics, and correlative studies from a first-in-human trial in recurrent glioblastoma. Results: ARL200 exposure activated DAP10/12-dependent signaling and downregulated multiple inhibitory immune checkpoint receptors, including CD200R1, PD1, and CTLA4, and checkpoint ligands, CD200 protein and PD-L1, through suppression of the JAK1-JAK3-SHP-STAT-IKK alpha beta-NF kappa B pathway. Distinct ARL200 variant peptides elicited unique immune responses. In patients with recurrent glioblastoma, ARL200 treatment was associated with immune activation, reduced inhibitory checkpoint expression, and evidence of antigen-specific memory responses without treatment-related toxicity. Conclusions: Targeting CD200AR enables coordinated modulation of multiple immune checkpoints with a single agent, representing a next-generation immunotherapeutic strategy opening a new pathway for treating aggressive malignancies.

10 November 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
RGRobert T Galvin
Robert T Galvin
ALAlex T Larsson
Alex T Larsson
MSMeghna Saxena
Meghna Saxena
GFGarrett Fitzpatrick
Garrett Fitzpatrick
DNDavid Nascene
David Nascene
KWKyle Williams
Kyle Williams
Background/Objectives: Histone H3 K27-altered diffuse midline gliomas (DMGs) have poor outcomes and are characterized by global loss of H3K27 trimethylation (H3K27me3). Evidence from other H3K27me3-deficient tumors suggests a potential vulnerability to combined histone deacetylase (HDAC) and MEK inhibition. We examined a clinical experience with this combination and tested its activity in glioma models. Methods: We reviewed the course of an 11-year-old with neurofibromatosis type 1 and a thoracic spinal DMG treated with selumetinib and vorinostat after gross-total resection, without upfront radiotherapy. In post hoc viability assays, we tested HDAC and MEK inhibition in two H3K27M-mutant glioma lines, an isogenic K27-rescued derivative, and two H3-wildtype lines. Combination benefit was measured as the reduction in area under the viability curve relative to vorinostat alone. Results: The patient experienced 22 months of radiotherapy-free, progression-free survival before recurrence, with a postoperative enhancing focus resolving during treatment. Treatment was associated with grade 1 diarrhea and dermatitis. In vitro, combination benefit was greater in the H3K27M-mutant lines than in the H3-wildtype lines (mean difference, 13.2; 95% confidence interval, 8.1–18.3; p < 0.001). Benefit was also greater in DIPG17 than in its K27-rescued derivative (mean difference, 22.4; 95% confidence interval, 10.1–34.7; p = 0.015). Conclusions: This clinical observation and the post hoc validation experiments support prospective study of H3K27me3 loss as a candidate biomarker for combined HDAC and MEK inhibition.